FDA reported that the drug is the first oral treatment formula against COVID-19. In the statement, it was stated that the drug is believed to be a valuable tool in reducing hospitalizations and deaths.
The drug, which will be sold by prescription under the name “Paxlovid”, will be used in the treatment of high-risk patients over the age of 12.
Oral medication will need to be taken quickly after diagnosis of COVID-19 and within 5 days of onset of symptoms.
It was announced that it reduced hospitalization and death rates by 89 percent.
On November 16, Pfizer applied to the FDA for the drug it developed against COVID-19 to be used in the treatment of intermediate and high-risk patients and only those who have not been vaccinated.
The US pharmaceutical company announced that its drug reduced hospitalization and death rates by 89 percent in moderate and high-risk patients.
Merck, another US pharmaceutical company, applied to the FDA on October 11 for an emergency use approval for the drug it developed against COVID-19.
England was the first country to approve the use of the drug “Molnupiravir” produced by Merck. Merck reported that molnupiravir reduces the risk of hospitalization and death by 50 percent in people who have just contracted the virus.